COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia

Figures & data

Table 1 Indicators, Milestones and Targets to End the Global TB Epidemic.⁷

Indicators	Milestones		Targets
	2020	2025	2030	2035
Reduction in number of TB deaths*	35%	75%	90%	95%
Reduction in TB incidence rate*	20%	50%	80%	90%
TB-affected families facing catastrophic costs due to TB	0%	0%	0%	0%

Note: *Compared with 2015.

Table 2 Fixed Dose Combinations for TB Patients

Body Weight (kg)	Initial Phase		Advanced Phase
Category 1	56 days		16 weeks
	HRZE (75/150/400/275)		HR (75/150)
30–37	2 tablets		2 tablets
38–54	3 tablets		3 tablets
55–70	4 tablets		4 tablets
≥71	5 tablets		5 tablets
Category 2	28 days	56 days	20 weeks
	HRZE	(HRZE)S (75/150/400/275) + S	HRE(75/150/275)
30–37	2 tablets	2 tab HRZE, 500 mg streptomycin inj	2 tablets
38–54	3 tablets	3 tab HRZE, 750 mg streptomycin inj	3 tablets
55–70	4 tablets	4 tab HRZE, 1000 mg streptomycin inj	4 tablets
≥71	5 tablets	5 tab HRZE, 1000 mg streptomycin inj	5 tablets
Paediatric	2 months		4–10 months
	HRZ (75/50/150)		HR (75/50)
5–7	1 tablet		1 tablet
8–11	2 tablets		2 tablets
12–16	3 tablets		3 tablets
17–22	4 tablets		4 tablets
23–30	5 tablets		5 tablets
>30	Follow adult anti-tuberculosis drug guidelines
New patients of drug-resistant TB treatment or treated for <1 month	8 months		12–14 months
	Km - Mfx - Pto - H - Cfz-E-Z/5Mfx-Cfz-E–Z
Drug resistant TB	20–26 months
Rifampicin resistant or MDR-TB	Km - Lfx - Eto - Cs - Z– (E) - (H)/Lfx– Eto - Cs - Z– (E) - (H)
Kanamycin resistant	Cm-Lfx-Eto-Cs-Z–(E)-(H)/Lfx- Eto-Cs-Z-(E)-(H)
Fluoroquinolones resistant	Km-Mfx-Eto-Cs-PAS-Z-(E)-(H)/Mfx-Eto-Cs-PAS-Z-(E)-(H).
	Km - Eto-Cs-PAS-Z-(E)- Bdq/Eto-Cs-PAS-Z-(E)
Second line injection resistant	Lfx-Eto-Cs-PAS-Z-(E)-Bdq/Lfx-Eto-Cs-PAS-Z-(E)
Kanamycin and fluoroquinolones resistant	Mfx-Eto-Cs-PAS-Z-(E)-(H)/Mfx-Eto-Cs-PAS-(E)-(H)
	Eto-Cs-PAS-Z-(E)-Bdq- Lnz– Cfz/Eto-Cs-PAS-Z-(E)-Lnz–Cfz

Abbreviations: H, isoniazid; R, rifampicin; Z, pyrazinamide; S, streptomycin; E, ethambutol; Lfx, levofloxacin; Mfx, moxifloxacin; Km, kanamycin; Cm, capreomycin; Eto, etionamide; Cfz, clofazimine; Lzd, linezolid; Bdq, bedaquiline; PAS, para-aminosalicylic acid.

Figure 1 COVID-19 pandemic disruptions on TB control management in Indonesia.

Figure 2 A comprehensive strategy to end TB in Indonesia, which is adapted from WHO’s recommendations.

Notes: Adapted with permission from World Health Organization. The End TB Strategy; 2015 [cited 8 February 2021]. Available from: https://www.who.int/tb/End_TB_brochure.pdf. Accessed January 13, 2022.⁷ © World Health Organization 2015.

WHO. The end TB strategy; [cited February 8, 2021]. Available from: https://www.who.int/tb/End_TB_brochure.pdf. Accessed January 13, 2022.

 Google Scholar